A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer.
Zin W MyintWilliam H St ClairStephen E StrupDonglin YanNing LiDerek B AllisonLaurie E McLouthCarleton S EllisPeng WangAndrew C JamesPatrick J HensleyDanielle E OttoSusanne M ArnoldRobert S DiPaolaJill M KolesarPublished in: Cancers (2023)
Epidiolex at a dose of 800 mg daily appears to be safe and tolerable in patients with BCR prostate cancer supporting a safe dose for future studies.